Covant Therapeutics Collaborates with Boehringer Ingelheim
Wednesday, March 29, 2023
Covant Therapeutics has entered into an exclusive research collaboration and worldwide licencing agreement with Boehringer Ingelheim covering Covant’s ADAR1 programme. The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients. ADAR1 is an exciting immuno-oncology target with significant therapeutic potential.
Under the terms of the agreement, Covant will be responsible for the discovery of ADAR1 small molecule inhibitors. This partnership with Covant’s exceptional scientific team and powerful platform, enables to bring next-generation immunotherapies to cancer patients.
The Covant-Boehringer Ingelheim collaboration seeks to create an ADAR1 inhibitor which is used in combination with other immunotherapies to increase the efficacy. To date, existing immunotherapies have revolutionised cancer treatment but only work in a minority of patients. Inhibiting ADAR1 has the potential to address this challenge by transforming “cold” tumours into “hot” tumours, which have more immune cells present in the tumour micro-environment.
